Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
出版年份 2023 全文链接
标题
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
作者
关键词
-
出版物
ESMO Open
Volume 8, Issue 1, Pages 100762
出版商
Elsevier BV
发表日期
2023-01-06
DOI
10.1016/j.esmoop.2022.100762
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
- (2022) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
- (2022) Changsong Qi et al. NATURE MEDICINE
- Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
- (2022) Keren Jia et al. BMC Medicine
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
- (2021) Bogdan Silviu Ungureanu et al. Frontiers in Oncology
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
- (2020) V. Gambardella et al. CANCER TREATMENT REVIEWS
- Enrichment of CLDN18 -ARHGAP fusion gene in gastric cancers in young adults
- (2019) Izuma Nakayama et al. CANCER SCIENCE
- Targeting Tumor-Associated Macrophages in Cancer
- (2019) Paulina Pathria et al. TRENDS IN IMMUNOLOGY
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases
- (2019) Irene Coati et al. BRITISH JOURNAL OF CANCER
- Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
- (2019) Matthias Dottermusch et al. VIRCHOWS ARCHIV
- 836TiPGLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
- (2019) M Shah et al. ANNALS OF ONCOLOGY
- Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer
- (2019) JIN HO BAEK et al. ANTICANCER RESEARCH
- Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer
- (2018) Akihito Kawazoe et al. Gastric Cancer
- Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
- (2018) Yang Shu et al. Nature Communications
- Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset
- (2018) Atsushi Tanaka et al. Oncotarget
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Macrophage Checkpoint Blockade in Cancer — Back to the Future
- (2018) Alberto Mantovani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
- (2017) Prabhsimranjot Singh et al. Journal of Hematology & Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now